• Drug Discovery. Accelerated.


  • twoXAR is an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships.


    Our computational platform is a secure cloud-based solution that uses proprietary artificial intelligence to find unanticipated associations between drug and disease. Its disease-agnostic approach includes four distinct stages:

    1. Biological Data Extraction


    Sourcing, normalizing, and identifying disease signals in biological data sets


    2. Automated Model Generation


    Automatically generating a mathematical drug-disease model


    3. Feature Identification


    Extracting relevant factors from the model to guide drug classification


    4. Candidate Analysis


    Candidate analysis and classifying the efficacy of each drug using machine learning



    • Fast: typical engagement is from handshake to predictions in less than six months

    • Scalable: process data sets of any size in minutes using an elastic computing environment

    • Unbiased: predictions are based on statistical modeling – you control the amount of human input

    • Comprehensive: works with gene expression, protein-interaction, chemical structure, MOA, and clinical data, among others – it even handles noisy or incomplete assays

    • Agnostic: models work with any disease and have been tested on more than 20 diseases to date

    • User-friendly: predictions are summarized in easy-to-read PDF reports

    • No capex: service model requires no software license fees or local hardware installations

    Want to learn more about DUMA™ and how it worked in disease-specific case studies? Connect.


    Using our DUMA™ Drug Discovery Platform we are working with biopharmaceutical research teams to identify novel and repurposable drug candidates to expand drug pipelines. By working with twoXAR, you get the power of high-throughput screening without the time and capital expenses required performing traditional wet lab-based approaches or managing computational infrastructures.

    Prioritize Existing Candidates


    Screen existing candidate libraries with additional evidence to support further investigation or early termination


    Perform Targeted Searches


    Configurable to focus on specific targets or classes of drugs






    Use custom parameters to find candidates and assess their efficacy for repositioning or new indications



    We have identified a number of candidates in therapeutic areas including autoimmunology, oncology, and neurology and are actively working with a number of leading patient advocacy, academic research, and biopharmaceutical organizations.


    If you are at an advanced stage with discovery candidates and need additional real world data-driven support or you are seeking entirely new targets, we can help. Connect.


    Some of the organizations we are collaborating with on drug discovery and candidate prioritization include:


    There are no positions currently available. Please connect with us for future opportunities.


    twoXAR's founders share more than a name, they share a commitment to disrupting the drug discovery process and accelerating the development of new medicines for rare and common health conditions.  They are supported by a team of experts in data science and systems biology and a network of advisers that includes biopharmaceutical industry and clinical research veterans.

    Andrew A. Radin

    CEO & Co-Founder


    Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew  developed the company's proprietary algorithm and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. 

    Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in computer science from Rochester Institute of Technology.


    Andrew M. Radin

    CBO & Co-Founder


    Andrew M. Radin formerly worked as an investor in venture and private equity funds and has designed, built, and managed several small organizations. Andrew co-founded a mobile platform startup while at MIT. As Chief Business Officer of twoXAR, Andrew is focused on validating the market, identifying customers, building the team, and fundraising.


    Andrew holds a Master in Business Administration degree from MIT Sloan, a Bachelor of Science degree in biochemistry and cell biology from UCSD, and a Bachelor of Arts degree in economics from UCSD.


    Yen S Low, Aaron C Daugherty, Elizabeth A Schroeder, William Chen, Tina Seto, Susan Weber, Michael Lim, Trevor Hastie, MayaMathur, Manisha Desai, Carl Farrington, Andrew A Radin, Marina Sirota, Pragati Kenkare, Caroline A Thompson, Peter P Yu, Scarlett LGomez, George W Sledge Jr, Allison W Kurian, Nigam H Shah. Journal of the American Medical Informatics Association. EPub: December 9, 2016


  • twoXAR BLOG

    Recent Stories

    by: Andrew A. Radin
    CEO, twoXAR


    In September 2016, we announced a collaboration with the Asian Liver Center at Stanford University School of Medicine (the Asian Liver Center). The goal of this collaboration was to identify new drug candidates targeting hepatocellular carcinoma (HCC, the major form of adult liver cancer). Today, we announced a lead candidate, TXR-311, that has shown positive results in cell-based assays. I wanted to share a bit more background on liver cancer and details on why these results are exciting... read post here.

    by: Andrew A. Radin
    CEO, twoXAR


    Today we announced our collaboration with Santen, a world leader in the development of innovative ophthalmology treatments. Scientists at twoXAR will use our proprietary computational drug discovery platform to discover, screen and prioritize novel drug candidates with potential application in glaucoma. Santen will then develop and commercialize drug candidates arising from the collaboration. This collaboration is an exciting example of how artificial intelligence-driven approaches can move beyond supporting existing hypotheses and lead the discovery of new drugs. Combining twoXAR’s unique capabilities with Santen’s experience in ophthalmic product development and commercialization… read post here.

    See full blog at: medium.com/@twoXAR


    We’d love to connect with partners, future team members, and other computational biology folks. Contact us to arrange a meeting.

    221 Forest Ave
    Palo Alto,CA 94301
    (650) 382-2605